Amgen Inc (AMGN): Today's Featured Drugs Winner
(
) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.9%. By the end of trading, Amgen rose $3.73 (3.8%) to $102.06 on average volume. Throughout the day, 4,129,559 shares of Amgen exchanged hands as compared to its average daily volume of 3,731,100 shares. The stock ranged in a price between $98.02-$102.33 after having opened the day at $98.16 as compared to the previous trading day's close of $98.33. Other companies within the Drugs industry that increased today were:
(
), up 24.6%,
(
), up 14.9%,
(
), up 12.0% and
(
), up 10.5%.
Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $73.6 billion and is part of the health care sector. Shares are up 14.1% year to date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Amgen a buy, no analysts rate it a sell, and 12 rate it a hold.
TheStreet Ratings rates
Amgen
as a
. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.
- You can view the full Amgen Ratings Report.
On the negative front,
(
), down 34.9%,
(
), down 25.2%,
(
), down 10.3% and
Bacterin International Holdings
(
), down 8.7% , were all laggards within the drugs industry with
(
) being today's drugs industry laggard.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
null